AT&TSample data
AT&T · Workforce Opportunity

Pilot Population & Opportunity Sizing

Define the target population, model scenarios, and size the clinical and financial opportunity for the workforce health pilot.

Pilot Population Selector

Modeled
Scenario
Division
Region
2%
0.5%2%10%
Eligible population
30,000
All divisions
Projected enrollment
2,000
2% of covered lives
Started treatment
1,678
84% of enrolled
Active at 6 months
1,326
79% of started

Reconciled Economic Model

Annual · 12-month period
Program investment
$10.80M
$5,400/enrolled member/yr
Medical offsets
$3.42M
$1,708/enrolled member/yr
Gross workforce value
$11.40M
$8,146/treated employee/yr
Net modeled impact
$4.02M
offsets + workforce − investment
Program investment
enrolled × $5,400−$10.80M
Medical offsets
enrolled × $1,708$3.42M
Gross workforce value
treated employees (1,400) × $8,146$11.40M
Gross economic value
medical + workforce$14.82M
Program investment
−$10.80M
Net modeled economic impact$4.02M
EPS-eligible earnings+0.0434¢/shareafter-tax (25%) ÷ 6,946,000,000 diluted shares
Clinical improvement: 1,009 (76% of active at 6mo)·Not used as economic denominator — offsets & workforce value based on enrolled count
Approved assumptions
Covered lives100,000
GLP-1 eligibility30% of covered lives
Program cost$5,400/enrolled member/yr (all-in)
Medical offset$1,708/enrolled member/yr
Workforce value$8,146/treated employee/yr
Employee share70% of enrolled (dependents excluded from workforce value)

Gross workforce value ($8,146) includes overtime savings, temporary labor savings, absenteeism reduction, and productivity gains. These subcategories are not added separately to prevent double counting. Medical offsets are a distinct component, not included in workforce value. All figures are modeled, not realized cash savings.

Base scenario summary

At 2,000 enrolled members, the pilot is projected to generate $NaNK in cost avoidance against $NaNK in program investment, for a net modeled impact of $NaNK. Clinical reach: 1,009 members with measurable improvement.

Pilot implementation timeline

Phase 1

Population identification

Weeks 1-2

Define eligible population by division, region and health risk criteria. Confirm enrollment targets with HR and finance.

Phase 2

Enrollment & onboarding

Weeks 3-6

Open enrollment, baseline data collection, care team assignment and first therapy orders.

Phase 3

Active intervention

Weeks 7-26

Daily check-ins, coaching, therapy management and 90-day/6-month persistence tracking.

Phase 4

Outcomes validation

Weeks 27-52

Manager data validation, 12-month clinical outcomes review and financial impact assessment.

·

All figures illustrative · synthetic data · not validated financial results

Employee Privacy Protected by Design

Employer reporting is designed to present aggregate workforce and health-program insights without exposing individual clinical records. Small-group reporting restrictions help reduce the risk of employee identification.

Sample dataPrivacy-restricted reporting

Aggregated information is not described as HIPAA-de-identified unless applicable de-identification requirements have been satisfied and verified.

Sample Data — Demonstration Only. Fictional data, not actual patient records or validated outcomes.